Once-soaring Peregrine plunges 78.5% on Phase IIb bavituximab 'discrepancies'
This article was originally published in Scrip
Executive Summary
Peregrine Pharmaceuticals plunged 78.5% on the Nasdaq when its stock fell from $5.39 to $1.16 per share on 24 September after the company said investors should not rely on impressive Phase IIb overall survival (OS) data reported earlier in the month for bavituximab in the treatment of non-small-cell lung cancer (NSCLC) due to "major discrepancies" in information provided by a third-party vendor.